EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effects of SGLT ‐2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine‐N‐Oxide in Patients With Type‐2 Diabetes

Katja B Zimmer iD, Arne Gessner iD, Dennis Kannenkeril, Agnes Bosch, Armin Ströbel iD, Roland E Schmieder, Renke Maas iD

Endocrinology, Diabetes & Metabolism · 2026

DOI: 10.1002/edm2.70318 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2026. Verfasst von Katja B Zimmer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Methylamines. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors have become a key drug class in the treatment of Type 2 diabetes (T2D) due to their effectiveness in blood sugar control, but also for many other clinical indications because of beneficial effects on cardiovascular diseases and mortality. Therefore, the findings of a secondary analysis of the recent EMMY trial, in which acute myocardial infarction patients treated with empagliflozin had higher trimethylamine‐N‐oxide (TMAO) serum levels compared to placebo, were unexpected, as high TMAO concentrations in blood have previously been linked to adverse cardiovascular and mortality outcomes. In light of this, the aim of our study was to explore the effects of the SGLT‐2 inhibitors empagliflozin and dapagliflozin on plasma concentrations and renal clearance (Cl R ) in a T2D patient setting.

Methods

Plasma and 24‐h urine samples from two prospective, randomised, placebo‐controlled, double‐blind, cross‐over trials with T2D patients (empagliflozin N = 69, NCT02471963; dapagliflozin N = 54, NCT02383238), taken at baseline and after each treatment with either SGLT‐2 inhibitor or placebo, were measured for TMAO via LC–MS/MS.

Results

After treatment with an SGLT‐2 inhibitor, in the total of 123 patients, TMAO plasma levels were 11.5% higher compared to placebo ( p = 0.006) and Cl R of TMAO was reduced by 10.3% ( p = 0.048) without any relevant change in its urinary excretion ( p = 0.521). In the dapagliflozin trial, TMAO plasma concentration was 23.4% higher ( p = 0.021), and Cl R of TMAO was 22.6% lower ( p = 0.025) after treatment with dapagliflozin compared to placebo. For empagliflozin, a similar trend was observed, but did not reach statistical significance.

Conclusion

Treatment with an SGLT‐2 inhibitor was associated with a modest increase in plasma concentration of TMAO. Together with data from a previous trial, the present findings suggest a possible class effect of SGLT‐2 inhibitors. Whether this effect impacts the overall clinical benefits of SGLT‐2 inhibitors needs to be subject to further investigations. Trial Registration http://www.clinicaltrials.gov : NCT02471963 (registered 15th June 2015, retrospectively registered) and NCT02383238

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsDiabetes Mellitus, Type 2GlucosidesMethylaminesSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedBiomarkersCross-Over StudiesDouble-Blind MethodProspective Studies

Stichwörter der Autor:innen

SGLT‐2 inhibitorsType 2 diabetes mellitustrimethylamine N‐oxide

Substanzen

Benzhydryl CompoundsBiomarkersdapagliflozinempagliflozinGlucosidesMethylaminesSodium-Glucose Transporter 2 Inhibitorstrimethyloxamine

Autor:innen und Institutionen

  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Department of Medicine 4 - Nephrology and Hypertension, Universitätsklinikum Erlangen, Erlangen, Germany.
  • Center for Clinical Studies, Universitätsklinikum Erlangen, Erlangen, Germany.

ORCID-Profile: Katja B Zimmer, Arne Gessner, Armin Ströbel, Renke Maas

Förderung

  • AstraZeneca
  • Boehringer Ingelheim

Zitieren

APA

Zimmer, K. B., Gessner, A., Kannenkeril, D., Bosch, A., Ströbel, A., Schmieder, R. E., & Maas, R. (2026). Effects of SGLT ‐2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine‐N‐Oxide in Patients With Type‐2 Diabetes. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70318

Vancouver

Zimmer KB, Gessner A, Kannenkeril D, Bosch A, Ströbel A, Schmieder RE, et al. Effects of SGLT ‐2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine‐N‐Oxide in Patients With Type‐2 Diabetes. Endocrinology, Diabetes & Metabolism. 2026. doi:10.1002/edm2.70318

BibTeX
@article{Zimmer2026,
  author = {Zimmer, Katja B and Gessner, Arne and Kannenkeril, Dennis and Bosch, Agnes and Ströbel, Armin and Schmieder, Roland E and Maas, Renke},
  title = {Effects of SGLT ‐2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine‐N‐Oxide in Patients With Type‐2 Diabetes},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  doi = {10.1002/edm2.70318}
}
Kostenlos starten →